XR 3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase

European Journal of Cancer

Volumn 35, Issue 6, 1999, Pages 1014-1019

  Donaldson, M J ^a   Skoumas, V ^a   Watson, M ^b   Ashworth, P A ^b   Ryder, H ^b   Moore, M ^b   Coombes, R C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Farnesyl transferase; Limonene; Perrilyl alcohol

Indexed keywords

4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; CARVONE; LIMONENE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21; UNCLASSIFIED DRUG; XR 3054; CYCLOHEXENE DERIVATIVE; P21(RAS) FARNESYL PROTEIN TRANSFERASE; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; TERPENE; TRANSFERASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL LINE; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; ONCOGENE RAS; PROTEIN PROCESSING;

ALKYL AND ARYL TRANSFERASES; CELL DIVISION; CYCLOHEXENES; GENES, RAS; HUMANS; PROTEIN ISOPRENYLATION; TERPENES; TUMOR CELLS, CULTURED;

EID: 0033137488     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00036-2     Document Type: Article

References (31)

1. Barbacid M. Ras genes. Ann Rev Biochem 1987, 56, 779-827.
2. Grand R.J.A., Owen D. The biochemistry of ras p21. Biochem. J. 279:1991;609-631.
3. Barbacid M. Human oncogenes 1986. In Devita VT, Hellman S and Rosenberg S. eds. Important Advances in Oncology. Philadelphia, J.B. Lippincott, 3-22.
4. Mulcahy L.S., Smith M.R., Stacey D.W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature. 313:1985;241-243.
5. Noda M., Ko M., Ogura A.et al. Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neuronal cell line. Nature. 318:1985;73-75.
6. Bar-Sagi D., Feramisco J.R. Microinjection of ras oncogene protein into PC12 cells induces morphological differentiation. Cell. 42:1985;841-848.
7. Kataoka T., Powers S., McGill C., Fasano O., Strathern J., Wigler M. Genetic analysis of yeast Ras1 and Ras2 genes. Cell. 37:1984;437-445.
8. McCormick F. The world according to GAP. Oncogene. 5:1990;1281-1283.
9. Leevers S.J., Paterson H.F., Marshall C.J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 369(6479):1994;411-414.
10. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4(1):1994;82-89.
11. Troppmair J., Bruder J.T., Munoz H.et al. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum and 12-0-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J. Biol. Chem. 269:1994;7030-7035.
12. Hancock J.F., Magee A.I., Childs J.E., Marshall C.J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 57:1989;1167-1171.
13. Hara H., Han M. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 92:1995;3333-3337.
14. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell. 77:1994;175-178.
15. Manne V., Yan N., Carboni J.M.et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene. 10:1995;1763-1779.
16. Elegbede J.A., Elson C.E., Qureshi A., Tanner M.A., Gould M.N. Inhibition of DMBA-induced mammary cancer by the monoterpene D-limonene. Carcinogenesis. 5:1998;661-664.
17. Chander S.K., Lansdowne A.G.B., Luqmani Y.A.et al. Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours. Br. J. Cancer. 69:1994;879-882.
18. Luqmani Y.A., Graham M., Coombes R.C. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer. 66:1992;273-280.
19. Skehan R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
20. Bishop W.R., Bond R., Petrin J.et al. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterisation and inhibition of Ras modification in transfected Cos cells. J. Biol. Chem. 270:1995;30611-30618.
21. Leftheris K., Kline T., Vite G.D.et al. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J. Med. Chem. 39(1):1996;224-236.
22. Ren Z., Elson C.E., Gould M.N. Inhibition of Type I and Type II geranylgeranyl-protein transferases in the monoterpene perillyl alcohol in HIH3T3 cells. Biochem. Pharmacol. 54:1997;113-120.
23. Sepp-Lorenzino L., Ma Z., Rands E.et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
24. James G.L., Goldstein J.L., Brown M.S.et al. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science. 260:1993;1937-1942.
25. Nagase T., Kawata S., Tamura S.et al. Inhibition of cell growth of human hepatoma cell lines (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Int. J. Cancer. 65:1996;620-626.
26. Vigushin D.M., Poon G.K., Boddy A.et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Chemother. Pharmacol. 42:1998;111-117.
27. Poon G.K., Vigushin D., Griggs L.J., Rowlands M.G., Coombes R.C., Jarman M. Identification and characterisation of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectometry. Drug Metab. Disposition. 24:1996;565-571.
28. Jirtle R.L., Carr B.I., Scott C.D. Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-beta 1 during liver regeneration. J. Biol. Chem. 266:1991;22444-22450.
29. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu. Rev. Biochem. 61:1992;307-330.
30. Dennis P.A., Rifkin D.B. Cellular activation if latent transforming growth factor-β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. USA. 88:1991;580-584.
31. Mills J.J., Chari R.S., Boyer I.J., Gould M.N., Jirtle R.L. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res. 55:1995;979-983.